Janus Henderson Maintains >5% Stake in Sarepta Therapeutics
Ticker: SRPT · Form: SC 13G/A · Filed: Feb 13, 2024 · CIK: 873303
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, pharmaceuticals
TL;DR
**Janus Henderson still owns over 5% of Sarepta, showing continued institutional confidence.**
AI Summary
Janus Henderson Group PLC, a major investment advisor, filed an amended SC 13G/A on February 13, 2024, indicating its continued ownership of more than 5% of Sarepta Therapeutics, Inc.'s Common Stock as of December 31, 2023. This filing, Amendment No. 2, confirms that Janus Henderson remains a significant institutional holder in Sarepta, a pharmaceutical company. This matters to investors because large institutional holdings can signal confidence in a company's long-term prospects and can influence stock stability.
Why It Matters
This filing confirms a major institutional investor, Janus Henderson Group PLC, continues to hold a significant stake in Sarepta Therapeutics, which can be a positive signal for other investors.
Risk Assessment
Risk Level: low — This filing indicates stable institutional ownership, which generally reduces volatility and risk for the stock.
Analyst Insight
Investors should note the continued institutional interest in Sarepta Therapeutics, but this filing alone doesn't provide new information on share count changes or future intentions, so further research into Sarepta's fundamentals and Janus Henderson's other holdings would be prudent.
Key Players & Entities
- Janus Henderson Group PLC (company) — the reporting person and institutional investor
- Sarepta Therapeutics, Inc. (company) — the subject company whose stock is being reported
- Common Stock (other) — the class of securities owned by Janus Henderson
- December 31, 2023 (date) — the date of the event requiring the filing
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as indicated by 'FORM TYPE: SC 13G/A' and 'Amendment No.: 2*'.
Who is the reporting person in this filing?
The reporting person is JANUS HENDERSON GROUP PLC, as stated under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: JANUS HENDERSON GROUP PLC'.
What is the subject company whose securities are being reported?
The subject company is SAREPTA THERAPEUTICS, INC., as identified under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.' and 'Name of Issuer: SAREPTA THERAPEUTICS, INC.'.
What is the CUSIP number for the securities mentioned in the filing?
The CUSIP number for the Common Stock of Sarepta Therapeutics, Inc. is 803607100, as listed under 'CUSIP Number: 803607100'.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023, as specified under 'Date of Event Which Requires Filing of this Statement: 12/31/2023'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 13, 2024 regarding Sarepta Therapeutics, Inc. (SRPT).